- Home
- NBY vs KLTOW Comparison
NBY vs KLTOW Comparison
Compare NBY & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- KLTOW
- Stock Information
- Founded
- NBY 2000
- KLTOW N/A
- Country
- NBY United States
- KLTOW United States
- Employees
- NBY N/A
- KLTOW 3
- Industry
- NBY
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBY
- KLTOW Health Care
- Exchange
- NBY Nasdaq
- KLTOW Nasdaq
- Market Cap
- NBY 3.5M
- KLTOW N/A
- IPO Year
- NBY 2007
- KLTOW 2022
- Fundamental
- Price
- NBY $0.62
- KLTOW $0.25
- Analyst Decision
- NBY Strong Buy
- KLTOW
- Analyst Count
- NBY 1
- KLTOW 0
- Target Price
- NBY $0.85
- KLTOW N/A
- AVG Volume (30 Days)
- NBY 32.4K
- KLTOW N/A
- Earning Date
- NBY 08-12-2025
- KLTOW N/A
- Dividend Yield
- NBY N/A
- KLTOW N/A
- EPS Growth
- NBY N/A
- KLTOW N/A
- EPS
- NBY 0.57
- KLTOW N/A
- Revenue
- NBY $9,781,000.00
- KLTOW N/A
- Revenue This Year
- NBY $23.91
- KLTOW N/A
- Revenue Next Year
- NBY $32.05
- KLTOW N/A
- P/E Ratio
- NBY $1.34
- KLTOW N/A
- Revenue Growth
- NBY 20.52
- KLTOW N/A
- 52 Week Low
- NBY $0.36
- KLTOW N/A
- 52 Week High
- NBY $2.45
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- NBY 56.70
- KLTOW N/A
- Support Level
- NBY $0.58
- KLTOW N/A
- Resistance Level
- NBY $0.64
- KLTOW N/A
- Average True Range (ATR)
- NBY 0.03
- KLTOW 0.00
- MACD
- NBY 0.00
- KLTOW 0.00
- Stochastic Oscillator
- NBY 62.38
- KLTOW 0.00
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.